title: Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.
abstract: OBJECTIVE
  To test the effect of atorvastatin (ATV) and ATV plus ω-3 FAEEs on VLDL-TG metabolism in obese, insulin resistant men.
  
  
  METHODS
  We carried out a 6-week randomized, placebo-controlled study to examine the effect of ATV (40 mg/day) and ATV plus ω-3 FAEEs (4 g/day) on VLDL-TG metabolism in 36 insulin resistant obese men. VLDL-TG kinetics were determined using d5 -glycerol, gas chromatography-mass spectrometry and compartmental modelling.
  
  
  RESULTS
  Compared with the placebo, ATV significantly decreased VLDL-TG concentration (-40%, p < 0.001) by increasing VLDL-TG fractional catabolic rate (FCR) (+47%, p < 0.01). ATV plus ω-3 FAEEs lowered VLDL-TG concentration to a greater degree compared with placebo (-46%, p < 0.001) or ATV monotherapy (-13%, p = 0.04). This was achieved by a reduction in VLDL-TG production rate (PR) compared with placebo (-32%, p = 0.008) or ATV (-20%, p = 0.03) as well as a reciprocal increase in VLDL-TG FCR (+42%, p < 0.05) compared with placebo.
  
  
  CONCLUSIONS
  In insulin resistant, dyslipidaemic, obese men, ATV improves VLDL-TG metabolism by increasing VLDL-TG FCR. The addition of 4 g/day ω-3 FAEE to statin therapy provides further TG-lowering by lowering VLDL-TG PR.
authors.affiliation: Metabolic Research Centre, School of Medicine and Pharmacology, The University of Western Australia, Nedlands, Australia.
authors.forename: T W K
authors.initials: TW
authors.lastname: Ng
authors.forename: E M M
authors.initials: EM
authors.lastname: Ooi
authors.forename: G F
authors.initials: GF
authors.lastname: Watts
authors.forename: D C
authors.initials: DC
authors.lastname: Chan
authors.forename: P H R
authors.initials: PH
authors.lastname: Barrett
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage; D053299:Apolipoprotein B-100 / Q000097:blood; D000069059:Atorvastatin; D004281:Docosahexaenoic Acids / Q000008:administration & dosage*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000188:drug therapy / Q000378:metabolism; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage*; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D007333:Insulin Resistance; D008079:Lipoproteins, VLDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism; D011758:Pyrroles / Q000008:administration & dosage*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood*
chemical_list: D000924:Anticholesteremic Agents; D053299:Apolipoprotein B-100; D004338:Drug Combinations; D006538:Heptanoic Acids; D008079:Lipoproteins, VLDL; D011758:Pyrroles; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride; D004281:Docosahexaenoic Acids; D000069059:Atorvastatin; D015118:Eicosapentaenoic Acid; C405603:Omacor
keywords: atorvastatin; docosahexaenoic acid; eicosapentaenoic acid; omega-3 fatty acid ethyl esters; very-low-density lipoprotein kinetics